KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Raw Materials (2016 - 2019)

Jazz Pharmaceuticals has reported Raw Materials over the past 10 years, most recently at $7.1 million for Q1 2019.

  • Quarterly results put Raw Materials at $7.1 million for Q1 2019, changed N/A from a year ago — trailing twelve months through Mar 2019 was $7.1 million (changed N/A YoY), and the annual figure for FY2018 was $5.6 million, up 58.22%.
  • Raw Materials for Q1 2019 was $7.1 million at Jazz Pharmaceuticals, up from $5.6 million in the prior quarter.
  • Over the last five years, Raw Materials for JAZZ hit a ceiling of $7.1 million in Q1 2019 and a floor of $1.5 million in Q4 2016.
  • Median Raw Materials over the past 5 years was $2.7 million (2016), compared with a mean of $3.6 million.
  • Biggest five-year swings in Raw Materials: tumbled 40.68% in 2016 and later surged 128.96% in 2017.
  • Jazz Pharmaceuticals' Raw Materials stood at $2.6 million in 2015, then tumbled by 40.68% to $1.5 million in 2016, then skyrocketed by 128.96% to $3.5 million in 2017, then soared by 58.22% to $5.6 million in 2018, then rose by 27.37% to $7.1 million in 2019.
  • The last three reported values for Raw Materials were $7.1 million (Q1 2019), $5.6 million (Q4 2018), and $4.2 million (Q2 2018) per Business Quant data.